Guest Column | December 14, 2012

Rethink Transdermal

AnneMRoush

By Anne M. Roush, Business Development Director, Transdermal and Inhalation Technologies, 3M Drug Delivery Systems

In the face of a significant patent cliff, many companies in the pharmaceutical industry are seeking new ways to protect their brands as long as possible, and reformulation presents one of the most obvious ways to do this. Historically, these endeavors were undertaken on a reactionary basis, for example, when a drug product has enjoyed a successful run but is facing new competitive threats from generics. Contemporary product life-cycle management is more strategic, and employs a proactive approach to reformulation earlier in the product development cycle. In other cases, reformulation can be undertaken for product differentiation as a means to give patients and their caregivers more options, which better suit their needs.

VIEW THE GUEST COLUMN!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Pharmaceutical Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: